raloxifene hydrochloride has been researched along with Carcinoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heckman-Stoddard, B; Miller, E; Minasian, L; Pinsky, PF | 1 |
| Goldstein, RE; Klinge, CM; Kumar, A | 1 |
| Balaburski, GM; Dardes, RC; Haddad, B; Johnson, M; Jordan, VC; Kim, H; Klein-Szanto, A; Lee, ES; Liu, H; Ross, EA; Sengupta, S; Zhu, F | 1 |
| Diaz-Arrastia, CR; Saeed, M; Salama, SA; Salih, SM; Theiler, SK; Veenstra, TD; Williams-Brown, MY; Xu, X | 1 |
| Bandos, H; Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Weissfeld, JL; Wickerham, DL; Wolmark, N | 1 |
| Beckett, LA; Degregorio, MW; Gregg, JP; Marchisano-Karpman, C; Read, KC; Wurz, GT; Yu, Q | 1 |
| Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A | 1 |
| Avila, N; Eng-Wong, J; Forman, MR; Johnson, DV; Premkumar, A; Remaley, AT; Stratton, P; Venzon, DJ; Zujewski, J | 1 |
| Cohen, FJ; Glusman, J; Gradishar, W; Lu, Y; Sledge, GW; Vogel, C | 1 |
| Mamounas, EP | 1 |
| Fackenthal, JD; Olopade, MD; Olufunmilayo, I | 1 |
| Bentrem, DJ; Craig Jordan, V | 1 |
3 review(s) available for raloxifene hydrochloride and Carcinoma
| Article | Year |
|---|---|
Breast cancer chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States | 2000 |
Breast cancer genetics. Implications of clinical practice.
Topics: Age of Onset; Anticarcinogenic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Case Management; Cyclin D1; DNA Mutational Analysis; Estrogen Antagonists; Female; Gene Frequency; Genes, BRCA1; Genes, erbB-2; Genetic Counseling; Genetic Testing; Humans; Male; Mammography; Mastectomy; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Oncogenes; Ovarian Neoplasms; Ovariectomy; Phenotype; Raloxifene Hydrochloride; Retrospective Studies; Risk; Tamoxifen; Transcription Factors | 2000 |
Tamoxifen, raloxifene and the prevention of breast cancer.
Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2002 |
1 trial(s) available for raloxifene hydrochloride and Carcinoma
| Article | Year |
|---|---|
Gynecologic and hormonal effects of raloxifene in premenopausal women.
Topics: Adult; Breast Neoplasms; Calcium Carbonate; Carcinoma; Dehydroepiandrosterone Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; Genitalia, Female; Gonadal Steroid Hormones; Humans; Menstrual Cycle; Middle Aged; Polyps; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Diseases | 2007 |
8 other study(ies) available for raloxifene hydrochloride and Carcinoma
| Article | Year |
|---|---|
Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Topics: Aged; Breast Neoplasms; Carcinoma; Chemoprevention; Cohort Studies; Estrogen Antagonists; Female; Humans; Medicare; Medicare Part D; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States | 2018 |
Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Topics: Carcinoma; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Phosphorylation; Raloxifene Hydrochloride; RNA, Small Interfering; Signal Transduction; Tamoxifen; Thyroid Neoplasms | 2010 |
Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Xenograft Model Antitumor Assays | 2010 |
The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
Topics: Carcinoma; Cells, Cultured; DNA Adducts; Dose-Response Relationship, Drug; Drug Combinations; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Metabolic Networks and Pathways; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Cell Count; Combined Modality Therapy; Female; Humans; Mammography; Middle Aged; Neoplasm Invasiveness; Postmenopause; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2012 |
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinoma; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred SENCAR; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation | 2007 |
Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Confidence Intervals; Disease Progression; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Receptors, Estrogen; Remission Induction; Safety; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen | 2000 |